{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:18:48Z","timestamp":1788866328699,"version":"build-2803163510"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant ascites is a common complication of advanced ovarian cancer (OC) and gastrointestinal cancer (GI), significantly impacting metastasis, quality of life, and survival. Increased intestinal permeability can lead to blood or lymphatic infiltration and microbial translocation from the gastrointestinal or uterine tract. This study aimed to identify microbiota-derived metabolites in ascites from OC (stages II-III and IV) and GI patients, assessing their roles in tumor progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Malignant ascites samples from 18 OC and GI patients were analyzed using a four-dimensional (4D) untargeted metabolomics approach combining reversed-phase (RP) and hydrophilic interaction liquid chromatography (HILIC) with trapped ion mobility spectrometry time-of-flight mass spectrometry (timsTOF-MS). Additonally, a targeted flow cytometry-based cytokine panel was used to screen for inflammatory markers. Non-endogenous, microbiota-derived metabolites were identified through the Human Microbial Metabolome Database (MiMeDB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>OC stage IV exhibited metabolic profiles similar to GI cancers, while OC stage II-III differed significantly. Stage IV OC patients exhibited higher levels of 11 typically microbiome-derived metabolites, including 1-methylhistidine, 3-hydroxyanthranilic acid, 4-pyridoxic acid, biliverdin, butyryl-L-carnitine, hydroxypropionic acid, indole, lysophosphatidylinositol 18:1 (LPI 18:1), mevalonic acid, N-acetyl-L-phenylalanine, and nudifloramide, and lower levels of 5 metabolites, including benzyl alcohol, naringenin, o-cresol, octadecanedioic acid, and phenol, compared to stage II\u2013III. Correlation analysis revealed positive associations between IL-10 and metabolites such as glucosamine and LPCs, while MCP-1 positively correlated with benzyl alcohol and phenol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>4D metabolomics revealed distinct metabolic signatures in OC and GI ascites, highlighting microbiota-derived metabolites involved in lipid metabolism and inflammation. Metabolites like 3-hydroxyanthranilic acid, indole, and naringenin may serve as markers of disease progression and underscore the microbiota\u2019s role in shaping malignant ascites and tumor biology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40170-025-00391-5","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:28:02Z","timestamp":1747146482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Identification and impact of microbiota-derived metabolites in ascites of ovarian and gastrointestinal cancer"],"prefix":"10.1186","volume":"13","author":[{"given":"Sisi","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooyong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyuntae","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"B\u00e9zi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Mager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kommoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Sprengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"391_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287\u201399.","journal-title":"Int J Womens Health"},{"issue":"1","key":"391_CR2","first-page":"3","volume":"10","author":"R Patni","year":"2019","unstructured":"Patni R. Screening for ovarian cancer: an update. J Midlife Health. 2019;10(1):3\u20135.","journal-title":"J Midlife Health"},{"issue":"5","key":"391_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"391_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/00000658-198606000-00009","volume":"203","author":"RN Garrison","year":"1986","unstructured":"Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites. Clinical and experimental observations. Ann Surg. 1986;203(6):644\u201351.","journal-title":"Ann Surg"},{"issue":"5","key":"391_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM199402033300508","volume":"330","author":"BA Runyon","year":"1994","unstructured":"Runyon BA. Care of patients with Ascites. N Engl J Med. 1994;330(5):337\u201342.","journal-title":"N Engl J Med"},{"issue":"2","key":"391_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/clon.2002.0135","volume":"15","author":"EM Smith","year":"2003","unstructured":"Smith EM, Jayson GC. The current and future management of malignant Ascites. Clin Oncol (R Coll Radiol). 2003;15(2):59\u201372.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"6","key":"391_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","volume":"198","author":"RA Adam","year":"2004","unstructured":"Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198(6):999\u20131011.","journal-title":"J Am Coll Surg"},{"issue":"4","key":"391_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","volume":"6","author":"BK Zebrowski","year":"1999","unstructured":"Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant Ascites. Ann Surg Oncol. 1999;6(4):373\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"391_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2013","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18(1):1\u20139.","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"391_CR10","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/s41440-023-01334-7","volume":"46","author":"R Mizoguchi","year":"2023","unstructured":"Mizoguchi R, Karashima S, Miyajima Y, Ogura K, Kometani M, Aono D, et al. Impact of gut Microbiome on the renin-aldosterone system: Shika-machi super preventive health examination results. Hypertens Res. 2023;46(10):2280\u201392.","journal-title":"Hypertens Res"},{"issue":"9","key":"391_CR11","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1097\/HJH.0000000000001378","volume":"35","author":"L Wang","year":"2017","unstructured":"Wang L, Zhu Q, Lu A, Liu X, Zhang L, Xu C, et al. Sodium butyrate suppresses angiotensin II-induced hypertension by Inhibition of renal (pro)renin receptor and intrarenal renin-angiotensin system. J Hypertens. 2017;35(9):1899\u2013908.","journal-title":"J Hypertens"},{"issue":"10","key":"391_CR12","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/s41440-023-01384-x","volume":"46","author":"K Gotoh","year":"2023","unstructured":"Gotoh K, Shibata H. Association between the gut Microbiome and the renin-angiotensin-aldosterone system: a possible link via the activation of the immune system. Hypertens Res. 2023;46(10):2315\u20137.","journal-title":"Hypertens Res"},{"issue":"2","key":"391_CR13","first-page":"35","volume":"32","author":"EV Samochatova","year":"1987","unstructured":"Samochatova EV, Baidun LV, Rumiantsev AG, Korkina LG, Suslova TB. [Comparative study of the cytochemical, immunological and chemiluminescent indices of the blood and bone marrow cells in acute lympholeukemia]. Gematol Transfuziol. 1987;32(2):35\u20139.","journal-title":"Gematol Transfuziol"},{"issue":"12","key":"391_CR14","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","volume":"113","author":"EZ Gomaa","year":"2020","unstructured":"Gomaa EZ. Human gut microbiota\/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020;113(12):2019\u201340.","journal-title":"Antonie Van Leeuwenhoek"},{"key":"391_CR15","doi-asserted-by":"publisher","first-page":"101744","DOI":"10.1016\/j.arr.2022.101744","volume":"82","author":"NH Rashidah","year":"2022","unstructured":"Rashidah NH, Lim SM, Neoh CF, Majeed ABA, Tan MP, Khor HM, et al. Differential gut microbiota and intestinal permeability between frail and healthy older adults: A systematic review. Ageing Res Rev. 2022;82:101744.","journal-title":"Ageing Res Rev"},{"key":"391_CR16","doi-asserted-by":"crossref","unstructured":"Maslennikov R, Poluektova E, Zolnikova O, Sedova A, Kurbatova A, Shulpekova Y et al. Gut microbiota and bacterial translocation in the pathogenesis of liver fibrosis. Int J Mol Sci. 2023;24(22).","DOI":"10.3390\/ijms242216502"},{"issue":"3","key":"391_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00423-017-1577-6","volume":"402","author":"S Komatsu","year":"2017","unstructured":"Komatsu S, Yokoyama Y, Nagino M. Gut microbiota and bacterial translocation in digestive surgery: the impact of probiotics. Langenbecks Arch Surg. 2017;402(3):401\u201316.","journal-title":"Langenbecks Arch Surg"},{"issue":"18","key":"391_CR18","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2023.5997","volume":"329","author":"EB Tapper","year":"2023","unstructured":"Tapper EB, Parikh ND. Diagnosis and management of cirrhosis and its complications: A review. JAMA. 2023;329(18):1589\u2013602.","journal-title":"JAMA"},{"issue":"10","key":"391_CR19","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1001\/jama.299.10.1166","volume":"299","author":"CL Wong","year":"2008","unstructured":"Wong CL, Holroyd-Leduc J, Thorpe KE, Straus SE. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results? JAMA. 2008;299(10):1166\u201378.","journal-title":"JAMA"},{"issue":"2","key":"391_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/hep.31884","volume":"74","author":"SW Biggins","year":"2021","unstructured":"Biggins SW, Angeli P, Garcia-Tsao G, Gines P, Ling SC, Nadim MK, et al. Diagnosis, evaluation, and management of Ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;74(2):1014\u201348.","journal-title":"Hepatology"},{"issue":"1","key":"391_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12967-022-03763-3","volume":"20","author":"Q Yang","year":"2022","unstructured":"Yang Q, Bae G, Nadiradze G, Castagna A, Berezhnoy G, Zizmare L, et al. Acidic Ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients. J Transl Med. 2022;20(1):581.","journal-title":"J Transl Med"},{"issue":"7","key":"391_CR22","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.7150\/thno.70194","volume":"12","author":"Y Xuan","year":"2022","unstructured":"Xuan Y, Wang H, Yung MM, Chen F, Chan WS, Chan YS, et al. SCD1\/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells. Theranostics. 2022;12(7):3534\u201352.","journal-title":"Theranostics"},{"issue":"3","key":"391_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11306-007-0082-2","volume":"3","author":"LW Sumner","year":"2007","unstructured":"Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, et al. Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI). Metabolomics. 2007;3(3):211\u201321.","journal-title":"Metabolomics"},{"issue":"D1","key":"391_CR24","doi-asserted-by":"publisher","first-page":"D611","DOI":"10.1093\/nar\/gkac868","volume":"51","author":"DS Wishart","year":"2023","unstructured":"Wishart DS, Oler E, Peters H, Guo A, Girod S, Han S, et al. MiMeDB: the human microbial metabolome database. Nucleic Acids Res. 2023;51(D1):D611\u201320.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"391_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/bjs.1800830104","volume":"83","author":"SL Parsons","year":"1996","unstructured":"Parsons SL, Watson SA, Steele RJ. Malignant Ascites. Br J Surg. 1996;83(1):6\u201314.","journal-title":"Br J Surg"},{"issue":"4","key":"391_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4240\/wjgs.v4.i4.87","volume":"4","author":"SL Sangisetty","year":"2012","unstructured":"Sangisetty SL, Miner TJ. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4(4):87\u201395.","journal-title":"World J Gastrointest Surg"},{"issue":"4","key":"391_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB. Meeting the challenge of Ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273\u201382.","journal-title":"Nat Rev Cancer"},{"key":"391_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0065-2571(94)00022-U","volume":"35","author":"PD Brown","year":"1995","unstructured":"Brown PD. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul. 1995;35:293\u2013301.","journal-title":"Adv Enzyme Regul"},{"issue":"8","key":"391_CR29","first-page":"1899","volume":"4","author":"GJ Beattie","year":"1998","unstructured":"Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant Ascites. Clin Cancer Res. 1998;4(8):1899\u2013902.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"391_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/nrc3610","volume":"13","author":"RF Schwabe","year":"2013","unstructured":"Schwabe RF, Jobin C. The Microbiome and cancer. Nat Rev Cancer. 2013;13(11):800\u201312.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"391_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00281-012-0352-6","volume":"35","author":"SI Grivennikov","year":"2013","unstructured":"Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol. 2013;35(2):229\u201344.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"391_CR32","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1186\/s40064-016-2821-1","volume":"5","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Yu YB. Intestinal microbiota and chronic constipation. Springerplus. 2016;5(1):1130.","journal-title":"Springerplus"},{"issue":"4","key":"391_CR33","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","volume":"66","author":"P Schwabl","year":"2017","unstructured":"Schwabl P, Hambruch E, Seeland BA, Hayden H, Wagner M, Garnys L, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. J Hepatol. 2017;66(4):724\u201333.","journal-title":"J Hepatol"},{"issue":"3","key":"391_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/hep.30349","volume":"70","author":"L Munoz","year":"2019","unstructured":"Munoz L, Borrero MJ, Ubeda M, Conde E, Del Campo R, Rodriguez-Serrano M, et al. Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis. Hepatology. 2019;70(3):925\u201338.","journal-title":"Hepatology"},{"issue":"24","key":"391_CR35","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1056\/NEJMra1600266","volume":"375","author":"SV Lynch","year":"2016","unstructured":"Lynch SV, Pedersen O. The human intestinal Microbiome in health and disease. N Engl J Med. 2016;375(24):2369\u201379.","journal-title":"N Engl J Med"},{"key":"391_CR36","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fonc.2013.00256","volume":"3","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256.","journal-title":"Front Oncol"},{"issue":"2","key":"391_CR37","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00404-018-4952-9","volume":"299","author":"J Krugmann","year":"2019","unstructured":"Krugmann J, Schwarz CL, Melcher B, Sterlacci W, Ozalinskaite A, Lermann J, et al. Malignant Ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth hospital, 2006\u20132015. Arch Gynecol Obstet. 2019;299(2):515\u201323.","journal-title":"Arch Gynecol Obstet"},{"key":"391_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.biocel.2017.09.002","volume":"92","author":"J Mikula-Pietrasik","year":"2017","unstructured":"Mikula-Pietrasik J, Uruski P, Szubert S, Szpurek D, Sajdak S, Tykarski A, et al. Malignant Ascites determine the transmesothelial invasion of ovarian cancer cells. Int J Biochem Cell Biol. 2017;92:6\u201313.","journal-title":"Int J Biochem Cell Biol"},{"issue":"7","key":"391_CR39","doi-asserted-by":"publisher","first-page":"622","DOI":"10.2174\/138920008785821738","volume":"9","author":"G Neurauter","year":"2008","unstructured":"Neurauter G, Schrocksnadel K, Scholl-Burgi S, Sperner-Unterweger B, Schubert C, Ledochowski M, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab. 2008;9(7):622\u20137.","journal-title":"Curr Drug Metab"},{"issue":"7","key":"391_CR40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1139\/o92-085","volume":"70","author":"R Dahiya","year":"1992","unstructured":"Dahiya R, Boyle B, Goldberg BC, Yoon WH, Konety B, Chen K, et al. Metastasis-associated alterations in phospholipids and fatty acids of human prostatic adenocarcinoma cell lines. Biochem Cell Biol. 1992;70(7):548\u201354.","journal-title":"Biochem Cell Biol"},{"issue":"4","key":"391_CR41","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0090-4295(02)01755-7","volume":"60","author":"NS Radin","year":"2002","unstructured":"Radin NS. Cancer progression in the kidney and prostate: vital roles of sphingolipids in chemotherapy. Urology. 2002;60(4):562\u20138.","journal-title":"Urology"},{"issue":"3","key":"391_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41419-019-1303-0","volume":"10","author":"K Zheng","year":"2019","unstructured":"Zheng K, Chen Z, Feng H, Chen Y, Zhang C, Yu J, et al. Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin. Cell Death Dis. 2019;10(3):157.","journal-title":"Cell Death Dis"},{"issue":"24","key":"391_CR43","doi-asserted-by":"publisher","first-page":"25101","DOI":"10.1074\/jbc.M313662200","volume":"279","author":"N Marchesini","year":"2004","unstructured":"Marchesini N, Osta W, Bielawski J, Luberto C, Obeid LM, Hannun YA. Role for mammalian neutral Sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J Biol Chem. 2004;279(24):25101\u201311.","journal-title":"J Biol Chem"},{"issue":"5","key":"391_CR44","first-page":"4412","volume":"13","author":"F Jing","year":"2021","unstructured":"Jing F, Jing C, Dai X, Zhou G, Di S, Bi X, et al. Sphingomyelin synthase 2 but not sphingomyelin synthase 1 is upregulated in ovarian cancer and involved in migration, growth and survival via different mechanisms. Am J Transl Res. 2021;13(5):4412\u201321.","journal-title":"Am J Transl Res"},{"key":"391_CR45","volume-title":"National academies of sciences E, and medicine. Ovarian cancers: evolving paradigms in research and care","author":"Committee on the State of the Science in Ovarian Cancer Research; Board on Health Care Services; Institute of Medicine","year":"2016","unstructured":"Committee on the State of the Science in Ovarian Cancer Research; Board on Health Care Services; Institute of Medicine. National academies of sciences E, and medicine. Ovarian cancers: evolving paradigms in research and care. Washington (DC): National Academies Press (US); 2016."},{"key":"391_CR46","doi-asserted-by":"publisher","first-page":"102932","DOI":"10.1016\/j.ebiom.2020.102932","volume":"58","author":"R Eriksen","year":"2020","unstructured":"Eriksen R, Perez IG, Posma JM, Haid M, Sharma S, Prehn C, et al. Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: an IMI DIRECT study. EBioMedicine. 2020;58:102932.","journal-title":"EBioMedicine"},{"issue":"2","key":"391_CR47","first-page":"335","volume":"26","author":"N Khanlarkhani","year":"2022","unstructured":"Khanlarkhani N, Azizi E, Amidi F, Khodarahmian M, Salehi E, Pazhohan A, et al. Metabolic risk factors of ovarian cancer: a review. JBRA Assist Reprod. 2022;26(2):335\u201347.","journal-title":"JBRA Assist Reprod"},{"issue":"1","key":"391_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of Ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123(1):9\u201316.","journal-title":"Br J Cancer"},{"key":"391_CR49","doi-asserted-by":"crossref","unstructured":"Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A et al. What is the healthy gut microbiota composition?? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1).","DOI":"10.3390\/microorganisms7010014"},{"issue":"2","key":"391_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41579-020-0438-4","volume":"19","author":"KA Krautkramer","year":"2021","unstructured":"Krautkramer KA, Fan J, Backhed F. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol. 2021;19(2):77\u201394.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"391_CR51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrgastro.2016.165","volume":"13","author":"SJ O\u2019Keefe","year":"2016","unstructured":"O\u2019Keefe SJ. Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol. 2016;13(12):691\u2013706.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"391_CR52","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s00432-021-03729-w","volume":"147","author":"N Dalal","year":"2021","unstructured":"Dalal N, Jalandra R, Bayal N, Yadav AK, Harshulika, Sharma M, et al. Gut microbiota-derived metabolites in CRC progression and causation. J Cancer Res Clin Oncol. 2021;147(11):3141\u201355.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"391_CR53","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance Olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721\u201331.","journal-title":"Lancet Oncol"},{"issue":"26","key":"391_CR54","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer. N Engl J Med. 2018;379(26):2495\u2013505.","journal-title":"N Engl J Med"},{"issue":"3","key":"391_CR55","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall survival with maintenance Olaparib at a 7-Year Follow-Up in patients with newly diagnosed advanced ovarian Cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J Clin Oncol. 2023;41(3):609\u201317.","journal-title":"J Clin Oncol"},{"issue":"34","key":"391_CR56","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","volume":"40","author":"BJ Monk","year":"2022","unstructured":"Monk BJ, Parkinson C, Lim MC, O\u2019Malley DM, Oaknin A, Wilson MK, et al. A randomized, phase III trial to evaluate Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J Clin Oncol. 2022;40(34):3952\u201364.","journal-title":"J Clin Oncol"},{"issue":"2","key":"391_CR57","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","volume":"19","author":"EJ Lipson","year":"2013","unstructured":"Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19(2):462\u20138.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"391_CR58","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in tumors with Mismatch-Repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"issue":"9","key":"391_CR59","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182\u201391.","journal-title":"Lancet Oncol"},{"issue":"8","key":"391_CR60","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch Repair-Deficient\/Microsatellite Instability-High metastatic colorectal Cancer. J Clin Oncol. 2018;36(8):773\u20139.","journal-title":"J Clin Oncol"},{"issue":"9742","key":"391_CR61","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"6","key":"391_CR62","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","volume":"21","author":"YY Janjigian","year":"2020","unstructured":"Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821\u201331.","journal-title":"Lancet Oncol"},{"issue":"7890","key":"391_CR63","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 Blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330.","journal-title":"Nature"},{"issue":"15suppl","key":"391_CR64","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1200\/JCO.2020.38.15_suppl.4525","volume":"38","author":"D Takahari","year":"2020","unstructured":"Takahari D, Shoji H, Minashi K, Hara H, Chin K, Ooki A, et al. A phase Ib study of nivolumab plus trastuzumab with S-1\/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study): safety evaluation. J Clin Oncol. 2020;38(15suppl):4525.","journal-title":"J Clin Oncol"},{"issue":"21","key":"391_CR65","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"391_CR66","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, et al. T-Cell-Inflamed Gene-Expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318\u201327.","journal-title":"J Clin Oncol"},{"issue":"5","key":"391_CR67","first-page":"560","volume":"4","author":"J Villadolid","year":"2015","unstructured":"Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560\u201375.","journal-title":"Transl Lung Cancer Res"},{"key":"391_CR68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","volume":"60","author":"VR Belum","year":"2016","unstructured":"Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12\u201325.","journal-title":"Eur J Cancer"},{"issue":"7","key":"391_CR69","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/cup.13150","volume":"45","author":"C Trinidad","year":"2018","unstructured":"Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, et al. Dermatologic toxicity from immune checkpoint Blockade therapy with an interstitial granulomatous pattern. J Cutan Pathol. 2018;45(7):504\u20137.","journal-title":"J Cutan Pathol"},{"issue":"9","key":"391_CR70","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/cncr.27969","volume":"119","author":"JS Weber","year":"2013","unstructured":"Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS, Investigators MDX. Patterns of onset and resolution of immune-related adverse events of special interest with Ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675\u201382.","journal-title":"Cancer"},{"key":"391_CR71","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3389\/fimmu.2017.01547","volume":"8","author":"M Dougan","year":"2017","unstructured":"Dougan M. Checkpoint Blockade toxicity and immune homeostasis in the Gastrointestinal tract. Front Immunol. 2017;8:1547.","journal-title":"Front Immunol"},{"issue":"1","key":"391_CR72","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6(1):95.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"391_CR73","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1136\/gutjnl-2014-308541","volume":"64","author":"S Zeissig","year":"2015","unstructured":"Zeissig S, Petersen BS, Tomczak M, Melum E, Huc-Claustre E, Dougan SK, et al. Early-onset Crohn\u2019s disease and autoimmunity associated with a variant in CTLA-4. Gut. 2015;64(12):1889\u201397.","journal-title":"Gut"},{"issue":"34","key":"391_CR74","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","volume":"35","author":"HJ Hammers","year":"2017","unstructured":"Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the checkmate 016 study. J Clin Oncol. 2017;35(34):3851\u20138.","journal-title":"J Clin Oncol"},{"issue":"21","key":"391_CR75","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint Blockade. Cell. 2021;184(21):5309\u201337.","journal-title":"Cell"},{"issue":"2","key":"391_CR76","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/cncr.32468","volume":"126","author":"JN Bodor","year":"2020","unstructured":"Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint Inhibition in non-small cell lung cancer (NSCLC). Cancer. 2020;126(2):260\u201370.","journal-title":"Cancer"},{"issue":"12","key":"391_CR77","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 Blockade in patients with metastatic melanoma. Nat Med. 2019;25(12):1916\u201327.","journal-title":"Nat Med"},{"issue":"6371","key":"391_CR78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut Microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"issue":"6529","key":"391_CR79","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595\u2013602.","journal-title":"Science"},{"issue":"12","key":"391_CR80","doi-asserted-by":"publisher","first-page":"100464","DOI":"10.1016\/j.xcrm.2021.100464","volume":"2","author":"SJ Blake","year":"2021","unstructured":"Blake SJ, James J, Ryan FJ, Caparros-Martin J, Eden GL, Tee YC, et al. The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. Cell Rep Med. 2021;2(12):100464.","journal-title":"Cell Rep Med"},{"issue":"4","key":"391_CR81","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF01311668","volume":"31","author":"L Marzio","year":"1986","unstructured":"Marzio L, Neri M, Di Giammarco AM, Cuccurullo F, Lanfranchi GA. Dopamine-induced migrating myoelectrical complex-like activity in human duodenum. Dig Dis Sci. 1986;31(4):349\u201354.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"391_CR82","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/BF01537410","volume":"35","author":"L Marzio","year":"1990","unstructured":"Marzio L, Neri M, Pieramico O, Delle Donne M, Peeters TL, Cuccurullo F. Dopamine interrupts Gastrointestinal fed motility pattern in humans. Effect on motilin and somatostatin blood levels. Dig Dis Sci. 1990;35(3):327\u201332.","journal-title":"Dig Dis Sci"},{"issue":"8","key":"391_CR83","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.tibtech.2017.04.001","volume":"35","author":"B Singh","year":"2017","unstructured":"Singh B, Mal G, Marotta F. Designer probiotics: paving the way to living therapeutics. Trends Biotechnol. 2017;35(8):679\u201382.","journal-title":"Trends Biotechnol"},{"key":"391_CR84","doi-asserted-by":"crossref","unstructured":"Knuplez E, Marsche G. An updated review of Pro- and Anti-Inflammatory properties of plasma lysophosphatidylcholines in the vascular system. Int J Mol Sci. 2020;21(12).","DOI":"10.3390\/ijms21124501"},{"issue":"6","key":"391_CR85","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1111\/jam.14441","volume":"127","author":"J Nie","year":"2019","unstructured":"Nie J, Zhang L, Zhao G, Du X. Quercetin reduces atherosclerotic lesions by altering the gut microbiota and reducing atherogenic lipid metabolites. J Appl Microbiol. 2019;127(6):1824\u201334.","journal-title":"J Appl Microbiol"},{"issue":"11","key":"391_CR86","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1210\/clinem\/dgae499","volume":"109","author":"S Sasidharan Pillai","year":"2024","unstructured":"Sasidharan Pillai S, Gagnon CA, Foster C, Ashraf AP. Exploring the gut microbiota: key insights into its role in obesity, metabolic syndrome, and type 2 diabetes. J Clin Endocrinol Metab. 2024;109(11):2709\u201319.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"391_CR87","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41564-022-01152-6","volume":"7","author":"SL Heaver","year":"2022","unstructured":"Heaver SL, Le HH, Tang P, Basle A, Mirretta Barone C, Vu DL, et al. Characterization of inositol lipid metabolism in gut-associated Bacteroidetes. Nat Microbiol. 2022;7(7):986\u20131000.","journal-title":"Nat Microbiol"},{"key":"391_CR88","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fimmu.2019.00277","volume":"10","author":"D Parada Venegas","year":"2019","unstructured":"Parada Venegas D, De la Fuente MK, Landskron G, Gonzalez MJ, Quera R, Dijkstra G, et al. Short chain fatty acids (SCFAs)-Mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277.","journal-title":"Front Immunol"},{"issue":"7","key":"391_CR89","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10654-023-01014-3","volume":"38","author":"S Naudin","year":"2023","unstructured":"Naudin S, Sampson JN, Moore SC, Albanes D, Freedman ND, Weinstein SJ, et al. Lipidomics and pancreatic cancer risk in two prospective studies. Eur J Epidemiol. 2023;38(7):783\u201393.","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"391_CR90","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrm2329","volume":"9","author":"YA Hannun","year":"2008","unstructured":"Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139\u201350.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4789","key":"391_CR91","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1126\/science.3101176","volume":"235","author":"YA Hannun","year":"1987","unstructured":"Hannun YA, Bell RM. Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science. 1987;235(4789):670\u20134.","journal-title":"Science"},{"issue":"5052","key":"391_CR92","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1126\/science.1313189","volume":"255","author":"KA Dressler","year":"1992","unstructured":"Dressler KA, Mathias S, Kolesnick RN. Tumor necrosis factor-alpha activates the sphingomyelin signal transduction pathway in a cell-free system. Science. 1992;255(5052):1715\u20138.","journal-title":"Science"},{"issue":"3","key":"391_CR93","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/08830185.2021.1954638","volume":"41","author":"M Ala","year":"2022","unstructured":"Ala M. Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system. Int Rev Immunol. 2022;41(3):326\u201345.","journal-title":"Int Rev Immunol"},{"issue":"25","key":"391_CR94","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.2174\/1381612823666170622095324","volume":"23","author":"J Oellgaard","year":"2017","unstructured":"Oellgaard J, Winther SA, Hansen TS, Rossing P, von Scholten BJ. Trimethylamine N-oxide (TMAO) as a new potential therapeutic target for insulin resistance and Cancer. Curr Pharm Des. 2017;23(25):3699\u2013712.","journal-title":"Curr Pharm Des"},{"issue":"46","key":"391_CR95","doi-asserted-by":"publisher","first-page":"11231","DOI":"10.1021\/jf403523g","volume":"61","author":"CT Liu","year":"2013","unstructured":"Liu CT, Raghu R, Lin SH, Wang SY, Kuo CH, Tseng YJ, et al. Metabolomics of ginger essential oil against alcoholic fatty liver in mice. J Agric Food Chem. 2013;61(46):11231\u201340.","journal-title":"J Agric Food Chem"},{"issue":"34","key":"391_CR96","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1073\/pnas.0910258107","volume":"107","author":"JW Clendening","year":"2010","unstructured":"Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A. 2010;107(34):15051\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"391_CR97","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","volume":"2","author":"B Huang","year":"2020","unstructured":"Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2(2):132\u201341.","journal-title":"Nat Metab"},{"issue":"1\u20133","key":"391_CR98","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ejphar.2008.12.053","volume":"606","author":"X Dai","year":"2009","unstructured":"Dai X, Zhu BT. Suppression of T-cell response and prolongation of allograft survival in a rat model by Tryptophan catabolites. Eur J Pharmacol. 2009;606(1\u20133):225\u201332.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"391_CR99","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1039\/C6FO00187D","volume":"7","author":"K Lee","year":"2016","unstructured":"Lee K, Kwak JH, Pyo S. Inhibition of LPS-induced inflammatory mediators by 3-hydroxyanthranilic acid in macrophages through suppression of PI3K\/NF-kappaB signaling pathways. Food Funct. 2016;7(7):3073\u201382.","journal-title":"Food Funct"},{"key":"391_CR100","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2020.12.001","volume":"70","author":"A Fiore","year":"2021","unstructured":"Fiore A, Murray PJ. Tryptophan and Indole metabolism in immune regulation. Curr Opin Immunol. 2021;70:7\u201314.","journal-title":"Curr Opin Immunol"},{"key":"391_CR101","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.molimm.2021.07.003","volume":"137","author":"J Yang","year":"2021","unstructured":"Yang J, Liu L, Li M, Huang X, Yang H, Li K. Naringenin inhibits pro\u2013inflammatory cytokine production in macrophages through inducing MT1G to suppress the activation of NF\u2013kappaB. Mol Immunol. 2021;137:155\u201362.","journal-title":"Mol Immunol"},{"issue":"4","key":"391_CR102","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/tox.22528","volume":"33","author":"MU Rehman","year":"2018","unstructured":"Rehman MU, Rahman Mir MU, Farooq A, Rashid SM, Ahmad B, Bilal Ahmad S, et al. Naringenin (4,5,7-trihydroxyflavanone) suppresses the development of precancerous lesions via controlling hyperproliferation and inflammation in the colon of Wistar rats. Environ Toxicol. 2018;33(4):422\u201335.","journal-title":"Environ Toxicol"},{"key":"391_CR103","doi-asserted-by":"publisher","first-page":"114990","DOI":"10.1016\/j.biopha.2023.114990","volume":"164","author":"J Cai","year":"2023","unstructured":"Cai J, Wen H, Zhou H, Zhang D, Lan D, Liu S, et al. Naringenin: A Flavanone with anti-inflammatory and anti-infective properties. Biomed Pharmacother. 2023;164:114990.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"391_CR104","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.4049\/jimmunol.1602016","volume":"199","author":"L Jin","year":"2017","unstructured":"Jin L, Zeng W, Zhang F, Zhang C, Liang W. Naringenin ameliorates acute inflammation by regulating intracellular cytokine degradation. J Immunol. 2017;199(10):3466\u201377.","journal-title":"J Immunol"},{"key":"391_CR105","doi-asserted-by":"crossref","unstructured":"Abotaleb M, Samuel SM, Varghese E, Varghese S, Kubatka P, Liskova A et al. Flavonoids in Cancer and apoptosis. Cancers (Basel). 2018;11(1).","DOI":"10.3390\/cancers11010028"},{"key":"391_CR106","doi-asserted-by":"crossref","unstructured":"Yahfoufi N, Alsadi N, Jambi M, Matar C. The Immunomodulatory and Anti-Inflammatory role of polyphenols. Nutrients. 2018;10(11).","DOI":"10.3390\/nu10111618"},{"issue":"2\u20133","key":"391_CR107","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12307-018-0215-3","volume":"11","author":"D Lane","year":"2018","unstructured":"Lane D, Matte I, Garde-Granger P, Bessette P, Piche A. Ascites IL-10 promotes ovarian Cancer cell migration. Cancer Microenviron. 2018;11(2\u20133):115\u201324.","journal-title":"Cancer Microenviron"},{"issue":"1","key":"391_CR108","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/1744-9987.12863","volume":"24","author":"T Ito","year":"2020","unstructured":"Ito T, Hanafusa N, Iwase S, Noiri E, Nangaku M, Nakagawa K, et al. Ascitic IL-10 concentration predicts prognosis of patients undergoing Cell-Free and concentrated Ascites reinfusion therapy. Ther Apher Dial. 2020;24(1):90\u20135.","journal-title":"Ther Apher Dial"},{"issue":"4","key":"391_CR109","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1600-0897.2010.00920.x","volume":"65","author":"Y Tao","year":"2011","unstructured":"Tao Y, Zhang Q, Huang W, Zhu H, Zhang D, Luo W. The peritoneal leptin, MCP-1 and TNF-alpha in the pathogenesis of endometriosis-associated infertility. Am J Reprod Immunol. 2011;65(4):403\u20136.","journal-title":"Am J Reprod Immunol"},{"issue":"3","key":"391_CR110","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.fertnstert.2007.12.067","volume":"91","author":"M Ulukus","year":"2009","unstructured":"Ulukus M, Ulukus EC, Tavmergen Goker EN, Tavmergen E, Zheng W, Arici A. Expression of interleukin-8 and monocyte chemotactic protein 1 in women with endometriosis. Fertil Steril. 2009;91(3):687\u201393.","journal-title":"Fertil Steril"},{"issue":"4","key":"391_CR111","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.8755-8920.2001.450401.x","volume":"45","author":"A Kharfi","year":"2001","unstructured":"Kharfi A, Akoum A. Correlation between decreased type-II interleukin-1 receptor and increased monocyte chemotactic protein-1 expression in the endometrium of women with endometriosis. Am J Reprod Immunol. 2001;45(4):193\u20139.","journal-title":"Am J Reprod Immunol"}],"container-title":["Cancer &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40170-025-00391-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T09:04:27Z","timestamp":1751015067000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerandmetabolism.biomedcentral.com\/articles\/10.1186\/s40170-025-00391-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["391"],"URL":"https:\/\/doi.org\/10.1186\/s40170-025-00391-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.04.03.25325183","asserted-by":"object"}]},"ISSN":["2049-3002"],"issn-type":[{"value":"2049-3002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from each patient prior to obtaining the sample to use for research purposes. Analyses of ascites samples was approved by the Ethics Committee, University of T\u00fcbingen, Germany (Ref. Nr. 696\/2016BO2 and 117\/2020BO1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"AG. S.D., W.K., K.C, Q.Y., Y.S., G.B., S.K., N.B., L.M.and J.S. declare that they have no competing interests. CT reports a research grant by Bruker Switzerland AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"21"}}